These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 7657411)

  • 1. The role of adjuvants in retroviral vaccines.
    Vogel FR
    Int J Immunopharmacol; 1995 Feb; 17(2):85-90. PubMed ID: 7657411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvants in perspective.
    Vogel FR
    Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving vaccine performance with adjuvants.
    Vogel FR
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvants for human vaccines--current status, problems and future prospects.
    Gupta RK; Siber GR
    Vaccine; 1995 Oct; 13(14):1263-76. PubMed ID: 8585280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
    Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
    J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers
    Ozorowski G; Cupo A; Golabek M; LoPiccolo M; Ketas TA; Cavallary M; Cottrell CA; Klasse PJ; Ward AB; Moore JP
    J Virol; 2018 Jul; 92(13):. PubMed ID: 29669838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvants in veterinary vaccines: modes of action and adverse effects.
    Spickler AR; Roth JA
    J Vet Intern Med; 2003; 17(3):273-81. PubMed ID: 12774966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biotechnology approaches to produce potent, self-adjuvanting antigen-adjuvant fusion protein subunit vaccines.
    Moyle PM
    Biotechnol Adv; 2017; 35(3):375-389. PubMed ID: 28288861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
    Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Composition and mode of action of adjuvants in licensed viral vaccines].
    Wagner R; Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Apr; 62(4):462-471. PubMed ID: 30830257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in vaccine adjuvants for infectious diseases.
    Singh M; Srivastava I
    Curr HIV Res; 2003 Jul; 1(3):309-20. PubMed ID: 15046255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in vaccine adjuvants for systemic and mucosal administration.
    O'Hagan DT
    J Pharm Pharmacol; 1998 Jan; 50(1):1-10. PubMed ID: 9504429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvants for HIV vaccines.
    Rao M; Alving CR
    Curr Opin HIV AIDS; 2016 Nov; 11(6):585-592. PubMed ID: 27607594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity.
    Richards RL; Alving CR; Wassef NM
    J Pharm Sci; 1996 Dec; 85(12):1286-9. PubMed ID: 8961140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of vaccine adjuvants using polymeric nanoparticles and their potential applications for anti-HIV vaccine].
    Akagi T; Baba M; Akashi M
    Yakugaku Zasshi; 2007 Feb; 127(2):307-17. PubMed ID: 17268151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.